61 results
8-K
EX-99.1
OCUL
Ocular Therapeutix Inc
7 May 24
Ocular Therapeutix™ Reports First Quarter 2024 Results
4:10pm
assets, OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert
S-3ASR
OCUL
Ocular Therapeutix Inc
25 Mar 24
Automatic shelf registration
4:40pm
insert) for the chronic treatment of dry eye disease, and several preclinical programs.
Corporate Information
We were incorporated under the laws … eye disease, and OTX-CSI for the chronic treatment of dry eye disease;
our commercialization efforts for our product DEXTENZA;
our plans to develop
8-K
EX-99.1
OCUL
Ocular Therapeutix Inc
11 Mar 24
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
4:10pm
) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry
8-K
EX-99.1
itp6aqmwnz9ly
22 Feb 24
Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement
7:34am
424B5
tlta9nec xcf5sqgjno
14 Dec 23
Prospectus supplement for primary offering
4:09pm
8-K
EX-99.1
2t9b0l4z8 bo1
14 Dec 23
Ocular TherapeutixTM Announces Pricing of Public Offering of Common Stock
8:46am
424B5
ms99 19lcq7w8f
13 Dec 23
Prospectus supplement for primary offering
4:10pm
8-K
EX-99.1
7dzhe
7 Nov 23
Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update
4:04pm
8-K
EX-99.1
u9z0d71okl2582lf
7 Aug 23
Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update
4:06pm
8-K
EX-99.1
ks3t 276d2gob1
8 May 23
Ocular Therapeutix™ Provides First Quarter 2023 Financial Results and Corporate Update
4:04pm
8-K
EX-99.1
ap4lscm
7 Nov 22
Ocular Therapeutix™ Reports Third Quarter 2022 Financial Results and Business Update
4:04pm
8-K
EX-99.1
awo17ldj
8 Aug 22
Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update
4:09pm